{"id":"W4401792490","doi":"10.1093/oncolo/oyae215","title":"Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma","year":2024,"lang":"en","type":"review","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Foundation Medicine; EMD Serono; Eisai; National Cancer Institute; Aptitude Health; Natera; Seagen; Loxo Oncology; Astellas Pharma; Calithera Biosciences; Mirati Therapeutics; bluebird bio; Sanofi; Exelixis; Genentech; MEI Pharma; Regeneron Pharmaceuticals; Gilead Sciences; Merck KGaA; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Gemcitabine; Pembrolizumab; Avelumab; Carboplatin; Medicine; Chemotherapy; Cisplatin; Oncology; Nivolumab; Metastatic Urothelial Carcinoma; Regimen; Internal medicine; Urothelial carcinoma; Bladder cancer; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001573471,0.0002306461,0.0008016763,0.0008273704,0.0002636193,0.001108518,0.0006259063,0.0007994747,0.001209218],"category_scores_gemma":[0.003085172,0.0001401011,0.0005604399,0.001011271,0.000462799,0.001304094,0.0005913847,0.001719077,0.0004368376],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007347465,"about_ca_system_score_gemma":0.001518009,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001365601,"about_ca_topic_score_gemma":0.004665074,"domain_scores_codex":[0.9993436,0.0002492527,0.0001480742,0.00005966874,0.0001604943,0.00003890926],"domain_scores_gemma":[0.999016,0.0005227693,0.0001411505,0.00001822354,0.0002480585,0.00005375001],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001110594,0.00004022727,0.001146684,0.01159596,0.0001157806,0.0003635928,0.0002929898,0.0004368982,0.0007881685,0.003370794,0.0360501,0.9456878],"study_design_scores_gemma":[0.00006317384,0.0002152468,0.003714739,0.01070312,0.0003136165,0.001714465,0.0003171236,0.0002365848,0.0003619049,0.003323324,0.9790046,0.00003206744],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007776791,0.9929946,0.0002323618,0.004335058,0.0002452349,0.000007300348,0.00002610177,0.000008954908,0.001372655],"genre_scores_gemma":[0.006009264,0.9895025,0.0006921876,0.00279642,0.0005264178,0.00002148247,0.00007415046,0.000006617542,0.0003709233],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001573471,"threshold_uncertainty_score":0.008321404,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04167354747080428,"score_gpt":0.360458438488445,"score_spread":0.3187848910176407,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}